Anil Kumar Yadav
CERTIFICATE OF ATTENDANCE
Triangle Center of Excellence in Regulatory Science and Innovation
EMAIL: triangle_cersi@unc.edu
This is to certify that
attended Advancing Novel Surrogate Endpoints for Rare Disease Drug Development Workshop Date: May 18, 2026
Total Hours = 6.25
Hosted by the Triangle Center of Excellence in Regulatory Science and Innovation (CERSI) through a cooperative agreement with the U.S. Food and Drug Administration, the workshop was one of three required under FDA’s Rare Disease Endpoint Advancement (RDEA) Pilot Program in fulfillment of commitments under PDUFA VII and FDORA 2022.
WORKSHOP WEBSITE:
https://trianglecersi.org/news/workshop_novel_surrogate_endpoints_rare-diseases
May 25, 2026
Issue Date
Christin L. Daniels
Christin Daniels, MA
Executive Director
Distributed by:
AKY

Issued to

Anil Kumar Yadav

Want to report a typo or a mistake?

ORDER

Credential Verification

Issue date: May 25, 2026

ID: ecc1d2ae-0171-4b40-996e-d8851d9b2db0

Issued by

UNC

Type

Webinar

Level

Professional

Format

Online

Duration

8 hours

Price

Free

Description

The recipient of this certificate attended a workshop on Advancing Novel Surrogate Endpoints For Rare Disease Drug Development, hosted by the Triangle Center of Excellence in Regulatory Science and Innovation and the US FDA.

Skills

Regulatory Affairs Certification (RAC)

Continuing Medical Education

Earning Criteria

Watching

Attended Mechanistic and Translational Evidence Considerations for Supporting a Novel Surrogate Endpoint Biomarker (FDA Presentation)

Watching

Attended Pathways for Engagement with FDA related to Biomarker Science (FDA Presentation)

Watching

Attended Center for Biologics Evaluation and Research (CBER) Biologics License Application (BLA) Approval: Regulatory Considerations in Rare Diseases

Watching

Attended A Case Study of a Reasonably Likely Surrogate Endpoint (RLSE) in Rare Disease Drug Development (FDA Presentation)

Watching

Attended Developing Endpoints Using New Approach Methodologies (Invited Panelists)

Watching

Attended Use of Digital Health Technologies to Collect Endpoint Data (Invited Panelists)

Watching

Attended Harnessing Real-World Data to Improve Rare Disease Clinical Trials (Invited Panelists)